Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2019

View Archived Issues

AMP analogues with reduced toxicity

For whom the pain bell Tolls

Immune cell stress response may play role in chronic pain

Phase III portion of the LUME-Meso study does not meet primary endpoint

CCL5 as novel biomarker associated with poor prognosis in locally advanced pancreatic cancer

AC Immune initiates phase I study of ACI-3024

Adaptimmune starts SURPASS study with its next-generation SPEAR T cells targeting MAGE-A4

Phase I study of Novo Nordisk's NNC-0247-0829 begins

Phase I plans for NTRX-07, a highly selective and potent CB2 receptor agonist

Minimal radiation exposure to staff seen with Iomab-B in phase III SIERRA trial

Phase IIa data for NA-831 in patients with MCI and mild and moderate Alzheimer's disease presented

Bionomics divulges SCN9A blockers for pain

Medshine Discovery presents new compounds for tuberculosis

Sunshine Lake Pharma identifies AOC3 inhibitors

Adlai Nortye describes IDO1 inhibitors

New CD73 inhibitors identified by Abbisko Therapeutics

CTI amends pacritinib study protocol following end of phase IIa meeting with FDA

Pharmazz cleared in India to initiate phase III study of PMZ-1620 for acute ischemic stroke

Transgene cleared to begin phase I/IIa study of TG-6002 given by intrahepatic artery infusion

Spring Bank enters HBV research agreement with NIAID

Midatech reports data from first-in-human study of MTX-102 in type 1 diabetes

Imugene to acquire Vaxinia and license to oncolytic virus CF-33

NDX-1017 safety, pharmacokinetics and pharmacodynamics in healthy subjects reported

TRAF3 conditional knockout model points to TRAF3 degradation as a target for preventing osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...